Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
about
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.Acute myeloid leukemia targets for bispecific antibodies.CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
P2860
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Enhancing natural killer cell- ...... gands engaging NKG2D or NKp30.
@en
type
label
Enhancing natural killer cell- ...... gands engaging NKG2D or NKp30.
@en
prefLabel
Enhancing natural killer cell- ...... gands engaging NKG2D or NKp30.
@en
P2093
P2860
P50
P1433
P1476
Enhancing natural killer cell- ...... igands engaging NKG2D or NKp30
@en
P2093
Andreas Günther
Andreas Humpe
Jan Gj van de Winkel
Katja Klausz
Martin Gramatzki
Matthias Peipp
Matthias Ritgen
Michael Kneba
Monika Brüggemann
Roland Repp
P2860
P304
P356
10.1080/2162402X.2015.1058459
P577
2015-06-05T00:00:00Z